Just ask iiris
When you prescribe Xiidra, we want to make sure your patients get what they need—especially help verifying their benefits. What if they could call a number and get help from a real, live person? Just ask iiris—not just one person but a whole squad of special agents highly trained in helpfulness.
Your Xiidra coverage
Commercial insurance, government insurance, or no insurance at all? Your patients can ask iiris and we’ll help them verify their benefits and figure out their coverage.
Savings specialists, too
You know what else is our thing? Helping people save on their Xiidra prescription. If they’re eligible for any special offers or assistance programs, we’ll let them know. And we’ll help them sign up.
But wait, there’s more!
We can even grant your patients Xiidra iinsider™ status for info, special offers, refill reminders, and more beamed to their inbox or phone. All they have to do is ask iiris. Monday through Friday, 9 am through 8 pm ET.Want to learn more?
Xiidra iinsider™ card
Help eligible patients say hello to savings on their co-pay.
If your patients have commercial insurance or are paying cash, they may be eligible to receive their first 30-day prescription free and pay as little as $20 for refills–a savings of up to $250 if they have commercial insurance and $225 if they’re paying cash.*
If your patients have government insurance, they may be eligible to get their first 30-day prescription free.*
Patients can check eligibility and sign up right here.
Questions? Call 1-844-694-4747
*Additional restrictions may apply.
Xiidra patient site >
All of the important info your patients want to know about Xiidra, all in one place.
Xiidra brochure >
An introductory guide for patients starting treatment with Xiidra. This brochure encourages your patients to speak to you about Dry Eye Disease and Xiidra.
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
Safety and efficacy in pediatric patients below the age of 17 years have not been established.